Phase II study of rituximab containing induction chemotherapy (R-high-CHOP followed by CHASER) and high-dose chemotherapy (LEED) supported with auto-PBSCT for previously untreated patients with advanced mantle cell lymphoma(JCOG0406)
Phase 2
- Conditions
- newly diagnosed advanced mantle cell lymphoma
- Registration Number
- JPRN-UMIN000001220
- Lead Sponsor
- Japan Clinical Oncology Group(JCOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
1) history of glaucoma 2) in-treatment diabetes mellitus with insulin, or uncontrollable diabetes mellitus 3) uncontrollable hypertension 4) treatemnt required coronary disease, myocardiopathy and/or heart failure, and/or in-treatment arrythmia 5) positibe test for HBs antigen 6) positive test for HCV antibody 7)positive test for HIV antibody 8) interstitial pneumonia, pulmonary fibrosis or severe pulmonaly emphysema 9) severe bacterial infection 10) active another neoplasm 11) pregnant woman, or possible pregnant woman, or lactating woman 12) psychological disease or psychological symptom that seems to bedisturbe to participate in clinical trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method